Current Generics Utilization and Associated Savings in Saudi Arabia: Insights From a Private Claims Database.

IF 1.4 Q3 HEALTH CARE SCIENCES & SERVICES

Value in health regional issues Pub Date : 2025-05-29 DOI:10.1016/j.vhri.2025.101138

Shabab AlGhamdi, Ibrahim Abdulrahman Aljuffali, Ahmed Hamdan Aljedai, Razan Aljaser, Mohammed Aljumah, Christiane Maskineh, Omar Aldibasi, Ghassan Sleilaty, Nada Ahmed Alagil

{"title":"Current Generics Utilization and Associated Savings in Saudi Arabia: Insights From a Private Claims Database.","authors":"Shabab AlGhamdi, Ibrahim Abdulrahman Aljuffali, Ahmed Hamdan Aljedai, Razan Aljaser, Mohammed Aljumah, Christiane Maskineh, Omar Aldibasi, Ghassan Sleilaty, Nada Ahmed Alagil","doi":"10.1016/j.vhri.2025.101138","DOIUrl":null,"url":null,"abstract":"Objectives: Generic substituting is a recognized policy fostering access to innovation while reducing healthcare expenditure. In the Kingdom of Saudi Arabia, the Council of Health Insurance (CHI) introduced a new policy, CHI circular N°289 (28 September 2022), incentivizing generic utilization. To date, there is no documentation on the uptake and outcome of this policy. This study aims to analyze the policy's impact on medication utilization and financial outcomes. The objectives are to assess the generic utilization trends and related cost savings, local versus imported brand usage, and the evolving landscape of pharmaceutical utilization.Methods: This is a 10-month retrospective observational study (September 2022-June 2023) using monthly aggregate data from the National Public Health Information Exchange System platform. Generic utilization rates, spending, and current and potential savings were estimated, and local generic uptake was assessed. Indirect comparisons were made with the Kingdom of Saudi Arabia's historical 2019 data.Results: Generic utilization rates increased from 70% to 76%, whereas generic spending rates increased from 38% to 44%. Local generics drove medication utilization rates (45%), outpacing imported generics (30%) and brand medications (25%). The observed trend, aligning with European and North American countries, exceeds 2019 figures. Over 10 months, current savings approximated 330 million Saudi Riyal, with potential savings of 228 million Saudi Riyal.Conclusions: CHI circular N°289 (28/09/2022) promoting generic medication use was widely adopted, a trend expected to continue.","PeriodicalId":23497,"journal":{"name":"Value in health regional issues","volume":" ","pages":"101138"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in health regional issues","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.vhri.2025.101138","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Generic substituting is a recognized policy fostering access to innovation while reducing healthcare expenditure. In the Kingdom of Saudi Arabia, the Council of Health Insurance (CHI) introduced a new policy, CHI circular N°289 (28 September 2022), incentivizing generic utilization. To date, there is no documentation on the uptake and outcome of this policy. This study aims to analyze the policy's impact on medication utilization and financial outcomes. The objectives are to assess the generic utilization trends and related cost savings, local versus imported brand usage, and the evolving landscape of pharmaceutical utilization.

Methods: This is a 10-month retrospective observational study (September 2022-June 2023) using monthly aggregate data from the National Public Health Information Exchange System platform. Generic utilization rates, spending, and current and potential savings were estimated, and local generic uptake was assessed. Indirect comparisons were made with the Kingdom of Saudi Arabia's historical 2019 data.

Results: Generic utilization rates increased from 70% to 76%, whereas generic spending rates increased from 38% to 44%. Local generics drove medication utilization rates (45%), outpacing imported generics (30%) and brand medications (25%). The observed trend, aligning with European and North American countries, exceeds 2019 figures. Over 10 months, current savings approximated 330 million Saudi Riyal, with potential savings of 228 million Saudi Riyal.

Conclusions: CHI circular N°289 (28/09/2022) promoting generic medication use was widely adopted, a trend expected to continue.

查看原文本刊更多论文

当前仿制药的利用和相关储蓄在沙特阿拉伯：从私人索赔数据库的见解。

目标：通用替代是一项公认的政策，促进获得创新，同时减少医疗保健支出。在沙特阿拉伯王国，健康保险委员会推出了一项新政策，即健康保险委员会第289号通告（2022年9月28日），鼓励通用利用。到目前为止，还没有关于这项政策的采纳和结果的文件。本研究旨在分析政策对药物使用和财务结果的影响。目的是评估仿制药的使用趋势和相关的成本节约，本地与进口品牌的使用情况，以及药物使用的发展前景。方法：这是一项为期10个月的回顾性观察研究（2022年9月至2023年6月），使用国家公共卫生信息交换系统平台的每月汇总数据。评估了通用利用率、支出以及当前和潜在的节省，并评估了当地通用的吸收情况。与沙特阿拉伯王国2019年的历史数据进行了间接比较。结果：仿制药使用率从70%上升到76%，而仿制药消费率从38%上升到44%。本地仿制药推动了药物使用率（45%），超过了进口仿制药（30%）和品牌药（25%）。观察到的趋势与欧洲和北美国家一致，超过了2019年的数字。在10个月的时间里，目前的储蓄约为3.3亿沙特里亚尔，潜在的储蓄为2.28亿沙特里亚尔。结论：促进仿制药使用的CHI通告N°289（28/09/2022）被广泛采用，这一趋势有望持续。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Value in health regional issues Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

CiteScore

2.60

自引率

5.00%

发文量

127